Xeris Biopharma Holdings Inc XERS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XERS is a good fit for your portfolio.
News
-
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
-
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
-
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
-
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
-
Xeris Biopharma Shares Climb 12% on Amgen License Agreement
-
Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment
-
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
-
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $2.04
- Day Range
- $2.11–2.28
- 52-Week Range
- $1.31–3.26
- Bid/Ask
- $2.18 / $2.22
- Market Cap
- $310.40 Mil
- Volume/Avg
- 3.2 Mil / 2.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.33%
Company Profile
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 377
- Website
- https://www.xerispharma.com
Comparables
Valuation
Metric
|
XERS
|
ICVX
|
EWTX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.30 | 4.03 |
Price/Sales | 1.86 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
XERS
|
ICVX
|
EWTX
|
---|---|---|---|
Quick Ratio | 1.17 | 17.59 | 18.98 |
Current Ratio | 1.64 | 18.06 | 19.50 |
Interest Coverage | −1.57 | — | — |
Quick Ratio
XERS
ICVX
EWTX
Profitability
Metric
|
XERS
|
ICVX
|
EWTX
|
---|---|---|---|
Return on Assets (Normalized) | −16.34% | −29.30% | −24.36% |
Return on Equity (Normalized) | −312.66% | −31.87% | −25.87% |
Return on Invested Capital (Normalized) | −13.88% | −34.69% | −29.82% |
Return on Assets
XERS
ICVX
EWTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vdlzwbnjx | Wxvy | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hrgfgfwbw | Vkqhk | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ssmlbvsj | Lxhnxj | $105.6 Bil | |
MRNA
| Moderna Inc | Rbbhqlxc | Gvvt | $40.8 Bil | |
ARGX
| argenx SE ADR | Pqflxpf | Bqlyr | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Lrjrkrfsf | Zyff | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zmngcqpmz | Vnwdyf | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sdtqlnyl | Tqrvsm | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jbrhmjsp | Sqhfpvc | $13.6 Bil | |
INCY
| Incyte Corp | Twnkyxgvz | Qccvzv | $12.8 Bil |